Evidence map›Paper›PMID 39888317›Full record

ArticleCancer research2025

A 3D Self-Assembly Platform Integrating Decellularized Matrix Recapitulates In Vivo Tumor Phenotypes and Heterogeneity.

Michael J Buckenmeyer, Elizabeth A Brooks, Madison S Taylor, Ireolu K Orenuga, Liping Yang, Ronald J Holewinski, Thomas J Meyer, Melissa Galloux, Marcial Garmendia-Cedillos, Thomas J Pohida and 3 more

Abstract read
In one paragraph

Article in Cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Barrier Function of the Extracellular Matrix in AAV Gene Therapy.Cellular and molecular bioengineering · 2026
    Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Michael J Buckenmeyer *Cancer Biomaterials Engineering Laboratory, Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0000-0003-2202-7215
Elizabeth A Brooks *Cancer Biomaterials Engineering Laboratory, Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0000-0002-8183-7085
Madison S TaylorCancer Biomaterials Engineering Laboratory, Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0000-0001-6810-1105
Ireolu K OrenugaCancer Biomaterials Engineering Laboratory, Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0009-0004-4402-5944
Liping YangTumor Angiogenesis Unit, Mouse Cancer Genetics Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0000-0001-9527-6015
Ronald J HolewinskiProtein Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland.ORCID 0000-0002-3337-3984
Thomas J MeyerCCR Collaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-7185-5597
Melissa GallouxIndependent Bioinformatician, Marseille, France.ORCID 0009-0009-4424-6815
Marcial Garmendia-CedillosInstrumentation Development and Engineering Application Solutions, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-1013-1835
Thomas J PohidaInstrumentation Development and Engineering Application Solutions, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-6093-2251
Thorkell AndressonProtein Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland.ORCID 0000-0002-9545-2450
Brad St CroixTumor Angiogenesis Unit, Mouse Cancer Genetics Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0000-0002-6246-0374
Matthew T WolfCancer Biomaterials Engineering Laboratory, Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0000-0002-0328-2475

Funding

Cancer Biomaterials EngineeringZIABC012021 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WOLF, MATTHEW · 2020 to 2025
$6.7M
Instrumentation Development and Engineering Application Solutions (IDEAS) Shared ResourceZICEB000103 · NIBIB · NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING · PI POHIDA, THOMAS · 2024 to 2025
$2.4M
Functional Analysis of TEM5 and TEM8Z01BC010484 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ST CROIX, BRADLEY D · 2003 to 2008
$529k
Intramural NIH HHS Z01 BC010484Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA BC012021Intramural NIH HHS ZIC EB000103National Cancer Institute (NCI)
6 · The paper itself

Abstract

Three-dimensional (3D) in vitro cell culture models are invaluable tools for investigating the tumor microenvironment. However, analyzing the impact of critical stromal elements, such as extracellular matrix (ECM), remains a challenge. In this study, we developed a hydrogel-free self-assembly platform to establish ECM-rich 3D "MatriSpheres" to deconvolute cancer cell-ECM interactions. Mouse and human colorectal cancer MatriSpheres actively incorporated microgram quantities of decellularized small intestine submucosa ECM, which proteomically mimicked colorectal cancer tumor ECM compared with traditional formulations like Matrigel. Solubilized ECM, at subgelation concentrations, was organized by colorectal cancer cells into intercellular stroma-like regions within 5 days, displaying morphologic similarity to colorectal cancer clinical pathology. MatriSpheres featured ECM-dependent transcriptional and cytokine profiles associated with malignancy, lipid metabolism, and immunoregulation. Model benchmarking with single-cell RNA sequencing demonstrated that MatriSpheres enhanced correlation with in vivo tumor cells over traditional ECM-poor spheroids. This facile approach enables tumor-specific tissue morphogenesis, promoting cell-ECM communication to improve fidelity for disease modeling applications. Significance: MatriSpheres provide a hydrogel-free 3D platform for decoupling the influence of heterogeneous extracellular matrix components on tumor biology and can broadly facilitate high-throughput drug discovery and screening applications. See related commentary by Ernst and De Wever, p. 1568.

Indexed as

Cell Culture Techniques, Three DimensionalColorectal NeoplasmsDecellularized Extracellular MatrixExtracellular MatrixAnimalsCell Line, TumorHumansMicePhenotypeSpheroids, CellularTumor MicroenvironmentDecellularized Extracellular Matrix

Identifiers

PMID39888317
PMCPMC12048290

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.